Abstract
Objective: To compare the efficacy and tolerability of mibefradil and amlodipine in patients with uncomplicated mild-to-moderate essential hypertension. Design: A double-blind, randomised, parallel group multicentre trial. Methods: 239 patients received 50 mg mibefradil or 5 mg amlodipine for 4 weeks, followed by a forced titration to 100 mg mibefradil or 10 mg amlodipine for an additional 8 weeks. Patients then entered a 4-week withdrawal period either on therapy or switched to placebo. Results: Statistically equivalent reductions in trough sitting diastolic blood pressure (SDBP) were observed after 12 weeks of once-daily treatment with 50/100 mg mibefradil (−11.5 ± 8.2 mm Hg) and 5/10 mg amlodipine (−13.2 ± 7.9 mm Hg). The number of patients with normalised SDBP (⩽90 mm Hg) increased 23.3% in the mibefradil group and 19.5% in the amlodipine group (approximately 74% in both groups). Patients on mibefradil or amlodipine during the withdrawal period had significantly larger decreases in SDBP than those on placebo. Patients on mibefradil had a decrease in heart rate of 5.5 bpm. Patients on amlodipine had no change in heart rate; however, cessation of amlodipine was associated with a decrease in heart rate. Conclusions: Mibefradil was as effective as amlodipine in reducing BP; both compounds were effective treatments of hypertension.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Viskoper, R., Bernink, P., Schelling, A. et al. A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. J Hum Hypertens 11, 387–393 (1997). https://doi.org/10.1038/sj.jhh.1000453
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1000453
Keywords
This article is cited by
-
Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension
Journal of Human Hypertension (2015)
-
Mechanism of voltage- and use-dependent block of class A Ca2+ channels by mibefradil
British Journal of Pharmacology (1998)